Research programme: megakaryocyte progenitor cell therapeutics - Cellerant Therapeutics

Alternative Names: CLT-009 - Cellerant Therapeutics

Latest Information Update: 16 Jul 2016

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Cellerant Therapeutics
Class Cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Preclinical Acute radiation syndrome
No development reported Thrombocytopenia

Most Recent Events

16 Jul 2016 No recent reports of development identified for preclinical development in Thrombocytopenia in USA (Parenteral)
11 Sep 2014 Preclinical trials in Acute radiation syndrome in USA (Parenteral)
10 Oct 2012 Cellerant Therapeutics receives a Small Business Innovation Research phase I and phase II option grant from the National Cancer Institute to develop CLT 009 for Thrombocytopenia

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.